News

EMA Validates Parallel Applications for Datopotamab Deruxtecan in Two Types of Cancer

March 08, 2024

EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.

Jacobs Announces Innovation Hub in Denmark

March 08, 2024

The facility producer’s new innovation hub will offer manufacturing, life sciences, and infrastructure services.

Europe's DARWIN EU Data Program Adds Capacity

March 08, 2024

EMA plans to add 10 partners to its real-world data initiative, DARWIN EU, in 2024.

J&J Completes $2 Billion Ambrx Acquisition, Boosts Pipeline for Next-Gen ADCs

March 07, 2024

Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.

Final Analytical Procedures Guidance Published

March 07, 2024

FDA has published final guidance documents regarding validation and development of analytical procedures.

AstraZeneca Set to Boost the UK’s Life Sciences Sector with Investment Plans

March 07, 2024

New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.

Cellares Innovates With Automated Cell and Gene Therapy Platform

March 07, 2024

Cellares CEO Fabian Gerlinghaus shares how an automated, closed-production platform with a small footprint can dramatically impact cost savings and scalability for cell and gene therapies.

AbbVie Partners with OSE Immunotherapeutics on Novel mAb for Chronic Inflammation

March 06, 2024

Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.

CordenPharma Expands Clinical Peptide Capacity

March 06, 2024

The company is expanding GMP capacities at its Frankfurt site to manufacture early clinical-phase peptide APIs.

Research into Cold Cancers Heating Up

March 04, 2024

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.